Fig. 3: Immunogenicity of the UF6b construct. | npj Vaccines

Fig. 3: Immunogenicity of the UF6b construct.

From: Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen

Fig. 3

a Mice were immunized (i.m.) following a longer D98 prime and two-boost regimen (boosts on Days 28 and 70) or a compressed D70 prime and two-boost regimen (boosts on Days 28 and 56) (20 μg/dose/mouse). Analyses of the longer regimen sera are shown in (b–e). b–d Mice were immunized with UF6b [gray] in the absence of adjuvant (b), with UF6b:GLA-LSQ [blue] (c), or with UF6b:AddaVax™ [orange] (d). e The kinetics of the antibody (1:100 dilution) response over time. Analyses of the shorter regimen sera are given in (f-g): (f) UF6b-specific ELISA with sera from mice immunized with UF6b with either GLA-LSQ [blue] or AddaVax™ [orange] in the 70-Day study. g Peptide 7 [P7] and peptide 9 [P9] specific ELISA of the same 70-Day study. ELISA analyses used pooled sera collected at the designated timepoints. Absorbances taken at 570 nm were deducted from absorbances at 450 nm to account for background. Error bars indicate SEM of triplicates; however, error was tightly controlled between replicates resulting in compact bars obscured by the data points. D, Day.

Back to article page